Bio-Rad Laboratories, Inc. (BIO)
| Previous Close | 279.31 |
| Open | 280.75 |
| Bid | 281.46 x 1200 |
| Ask | 282.02 x 3000 |
| Day's Range | 280.56 - 283.50 |
| 52 Week Range | 261.59 - 431.79 |
| Volume | |
| Avg. Volume | 211,546 |
| Market Cap | 8.043B |
| Beta (5Y Monthly) | 0.88 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -21.81 |
| Earnings Date | May 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 409.80 |
ZacksEarnings Preview: National Vision (EYE) Q1 Earnings Expected to Decline
National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Business WireBio-Rad’s Management to Participate in Fireside Chat During RBC Capital Markets Global Healthcare Conference
HERCULES, Calif., May 01, 2024--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Operating Officer Andy Last and Chief Financial Officer Roop K. Lakkaraju will participate in a fireside chat event during the RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024, at 2:05 PM Eastern Time (11:05 AM Pacific Time).
ZacksAnalysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
